EUVIMEDEUVIMED entdecken
Crossref

A novel bispecific peptide targeting PD-1 and PD-L1 with combined antitumor activity of T-cells derived from the patients with TSCC

Lili Wang, Junheng Zheng, Zhihao Tan, Yan Zhang, Hua Wang

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112582 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Lili Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, Clinical Laboratory, Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University, G…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Carcinoma, Squamous Cell, Peptides, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) are key immune checkpoints (ICs) that critically influence immunotherapy. Tumor resistance to single IC-targeting drugs has increased interest in dual-target drugs, which have shown feasibility for cancer treatment. In this study, we aimed to develop dual-target peptide drugs targeting the PD-1/PD-L1 pathway and to evaluate their efficacy compared to functional antibodies in enhancing the cytotoxicity of human T cells against tongue squamous carcinoma cell lines. Through sequence analysis and peptide truncation, we modified a pre-existing peptide named nABPD-1 targeting PD-1. Subsequently, we obtained two novel peptides named nABPD-2 and nABPD-3, with nABPD-2 showing an enhanced affinity for human PD-1 protein compared to nABPD-1. Importantly, nABPD-2 exhibited dual-targeting capability, possessing a high affinity for both PD-L1 and PD-1. Furthermore, nABPD-2 effectively promoted the cytotoxicity of human T cells against tongue squamous carcinoma cell lines, surpassing the efficacy of anti-PD-1 or anti-PD-L1 functional antibodies alone. Considering that nABPD-2 has lower production costs and dose requirements, it can potentially be used in therapeutic applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenCarcinoma, Squamous CellPeptidesProgrammed Cell Death 1 ReceptorTongue NeoplasmsHumansCell Line, TumorImmune Checkpoint InhibitorsImmunotherapyT-Lymphocytes

Stichwörter der Autor:innen

Bispecific peptidesCancer immunotherapyPD-1, PD-L1Tongue squamous cell carcinoma (TSCC)

Substanzen

B7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorsPDCD1 protein, humanPeptidesProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Oral and Maxillofacial Surgery, Clinical Laboratory, Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Stomatology, Guangzhou 510055, C…
  • Zhuhai Taisujian Biotechnology Co., Ltd, Zhuhai, Guangdong, China; Cheerland Taisujian BioPharm. Co., Ltd, Shenzhen, Guangdong, China.
  • Cheerland Taisujian BioPharm. Co., Ltd, Shenzhen, Guangdong, China.
  • Laboratory of Cancer and Stem Cell Biology, Key Laboratory of Gene Engineering of the Ministry of Education, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou Higher Educatio…

Zitieren

APA

Wang, L., Zheng, J., Tan, Z., Zhang, Y., & Wang, H. (2024). A novel bispecific peptide targeting PD-1 and PD-L1 with combined antitumor activity of T-cells derived from the patients with TSCC. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112582

Vancouver

Wang L, Zheng J, Tan Z, Zhang Y, Wang H. A novel bispecific peptide targeting PD-1 and PD-L1 with combined antitumor activity of T-cells derived from the patients with TSCC. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112582

BibTeX
@article{Wang2024,
  author = {Wang, Lili and Zheng, Junheng and Tan, Zhihao and Zhang, Yan and Wang, Hua},
  title = {A novel bispecific peptide targeting PD-1 and PD-L1 with combined antitumor activity of T-cells derived from the patients with TSCC},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112582}
}
Kostenlos starten →